Encontrados 2 documentos, a visualizar página 1 de 1
Doxorubicin versus doxorubicin and cisplatin in endometrial carcinoma: definiti...
Aapro, MS; Van Wijk, FH; Bolis, G; Chevallier, B; Van der Burg, ME; Oliveira, CFBACKGROUND: Combination chemotherapy yields better response rates which do not always lead to a survival advantage. The aim of this study was to investigate whether the reported differences in the efficacy and toxicity of monotherapy with doxorubicin (DOX) versus combination therapy with cisplatin (CDDP) in endometrial adenocarcinoma lead to significant advantage in favour of the combination. PATIENTS AND METHO...
Randomized phase III trial of bleomycin, vindesine, mitomycin-C, and cisplatin ...
Vermorken, JB; Zanetta, G; Oliveira, CF; Van der Burg, ME; Lacave, AJ; Teodorovic, IPURPOSE: Three previous mitomycin-cisplatin-based chemotherapy trials conducted within the EORTC Gynecological Cancer Cooperative Group (GCCG) in patients with disseminated squamous-cell carcinoma of the uterine cervix (SCCUC) suggested that with such regimens a higher overall response rate and a higher complete response rate could be obtained compared to what might have been expected from cisplatin alone. In t...
| Financiadores do RCAAP | |||||||
|
|
|
|
|
|
||